Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation

Open access
Takeda, Atsuya, Sanuki, Naoko, Tsurugai, Yuichiro, Iwabuchi, Shogo, Matsunaga, Kotaro, Ebinuma, Hirotoshi, Imajo, Kento, Aoki, Yousuke, Saito, Hidetsugu, Kunieda, Etsuo · 2016 · Cancer

Abstract

BACKGROUND: Curative treatment options for patients with early stage hepatocellular carcinoma (HCC) include resection, liver transplantation, and percutaneous ablation therapy. However, even patients with solitary HCC are not always amenable to these treatments. The authors prospectively investigated the clinical outcomes of patients who received stereotactic body radiotherapy (SBRT) for solitary HCC. METHODS: A phase 2 study involving SBRT and optional transarterial chemoembolization (TACE) was conducted in patients with Child‐Pugh grade A or B and underlying, solitary HCC (greatest tumor dimension, ≤4 cm) who were unsuitable candidates for resection and radiofrequency ablation. The prescription dose was 35 to 40 grays in 5 fractions. The primary endpoint was 3‐year local tumor control. RESULTS: From 2007 to 2012, 101 patients were enrolled, and 90 were evaluable with a median follow‐up of 41.7 months (range, 6.8‐96.2 months). Thirty‐two patients were treatment‐naïve, 20 were treated for newly diagnosed intrahepatic failure, and 38 were treated for residual or recurrent HCC as salvage therapy. Thirty‐two patients did not receive TACE, 48 received insufficient TACE, and 10 attained full lipiodol accumulation. The 3‐year local control rate was 96.3%, the 3‐year liver‐related cause‐specific survival rate was 72.5%, and the overall survival rate was 66.7%. Grade 3 laboratory abnormalities were observed in 6 patients, and 8 patients had Child‐Pugh scores that worsened by 2 points. CONCLUSIONS: SBRT achieved high local control and overall survival with feasible toxicities for patients with solitary HCC, despite rather stringent conditions. SBRT can be effective against solitary HCC in treatment‐naive, intrahepatic failure, residual disease, and recurrent settings, taking advantage of its distinctive characteristics. Cancer 2016;122:2041–9. © 2016 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.30008

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 203

Metadata

Authors
Takeda, A., Sanuki, N., Tsurugai, Y., Iwabuchi, S., Matsunaga, K., Ebinuma, H., Imajo, K., Aoki, Y., Saito, H., & Kunieda, E.
Venue
Cancer
Publisher
Wiley
Published
2016-04-08
Volume
122
Issue
13
Pages
2041-2049
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2338748777
Cited by
203
References
2
FWCI
12.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. https://app.cochat.ai/papers/10.1002/cncr.30008
The paper
Takeda, A., Sanuki, N., Tsurugai, Y., Iwabuchi, S., Matsunaga, K., Ebinuma, H., Imajo, K., Aoki, Y., Saito, H., & Kunieda, E. (2016). Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. https://doi.org/10.1002/cncr.30008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.